FDA Approves New 8-Week Maintenance Dosing for Eli Lilly's EBGLYSS

The U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing regimen for Eli Lilly and Company's (NYSE:LLY) EBGLYSS (lebrikizumab-lbkz), allowing adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every 8 weeks.

The Product

EBGLYSS is a monoclonal antibody that targets IL-13, a key protein in the inflammation associated with atopic dermatitis. Initially administered as weekly loading doses, patients then transition to maintenance dosing every 8 weeks. Clinical trials demonstrated improvements in skin clearance and itch reduction.

Pricing and Availability

Eli Lilly has not yet announced the price of EBGLYSS or insurance coverage details. The drug is expected to be available in U.S. pharmacies in the coming weeks.

Competition

EBGLYSS competes with other biologics such as Dupixent (Sanofi and Regeneron) and Adbry (LEO Pharma). Its less frequent dosing schedule (every 8 weeks) may offer a competitive advantage.

Potential Impact on the Company

This approval expands Eli Lilly's dermatology portfolio and could boost revenues in the atopic dermatitis market, which exceeds $10 billion globally. EBGLYSS is expected to contribute to LLY's sales growth in the coming years.